Compare SMTC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTC | EXEL |
|---|---|---|
| Founded | 1960 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 11.4B |
| IPO Year | 2000 | 2000 |
| Metric | SMTC | EXEL |
|---|---|---|
| Price | $106.57 | $46.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $93.20 | $46.50 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.65 | 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | ★ $1,049,975,000.00 | $452,477,000.00 |
| Revenue This Year | $20.10 | $13.61 |
| Revenue Next Year | $13.01 | $13.13 |
| P/E Ratio | ★ N/A | $16.83 |
| Revenue Growth | ★ 15.47 | N/A |
| 52 Week Low | $28.91 | $33.76 |
| 52 Week High | $110.55 | $48.74 |
| Indicator | SMTC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 62.50 |
| Support Level | $62.94 | $40.53 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.51 | 1.24 |
| MACD | 2.13 | 0.22 |
| Stochastic Oscillator | 86.76 | 78.81 |
Semtech Corp is a provider of high-performance semiconductors powering data center networking, Internet of Things ("IoT") connectivity, and cellular infrastructure solutions. The company designs, develops, manufactures, and markets a diverse portfolio of products for commercial applications, addressing the infrastructure, high-end consumer, and industrial end markets. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems, and Connected Services. The majority of the company's revenue is earned through the Analog Mixed Signal and Wireless segment. Geographically, the majority of the company's revenue is earned from the Asia Pacific region; the company also operates in North America and Europe.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.